









Markets
/
Stocks
/
nasdaq-prta
/

Prothena Corporation PLC

PRTA

9.260USD

-0.260-2.73%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

498.49MMarket Cap

LossP/E TTM



Prothena Corporation PLC

9.260

-0.260-2.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Prothena Corporation PLC

Currency: USD Updated: 2026-03-27

Key Insights

Prothena Corporation PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 110 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Prothena Corporation PLC's Score

Industry at a Glance

Industry Ranking

110 / 391

Overall Ranking

226 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Prothena Corporation PLC Highlights

StrengthsRisks

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.68M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.68M.

Overvalued

The company’s latest PE is -2.04, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 43.35M shares, decreasing 31.25% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 435.51K shares of this stock.

Analyst Rating

Based on 6 analysts

Hold

Current Rating

21.000

Target Price

+120.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Prothena Corporation PLC is 6.20, ranking 280 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 21.00K, representing a year-over-year decrease of 99.01%, while its net profit experienced a year-over-year decrease of 62.75%.

Score

Industry at a Glance

Previous score

6.20

Change



Financials

9.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.87

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Prothena Corporation PLC's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Prothena Corporation PLC is 7.12, ranking 167 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.04, which is -47.20% below the recent high of -1.08 and -1818.66% above the recent low of -39.18.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Prothena Corporation PLC is 6.86, ranking 324 out of 391 in the Biotechnology & Medical Research industry. The average price target is 18.50, with a high of 36.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

6.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Hold

Current Rating

21.000

Target Price

+120.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Prothena Corporation PLC

PRTA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Prothena Corporation PLC is 6.08, ranking 279 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.23 and the support level at 8.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.27

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.042

Neutral

RSI(14)

52.225

Neutral

STOCH(KDJ)(9,3,3)

69.115

Buy

ATR(14)

0.436

Low Volatility

CCI(14)

47.468

Neutral

Williams %R

53.369

Neutral

TRIX(12,20)

-0.086

Sell

StochRSI(14)

66.213

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

9.128

Buy

MA10

8.969

Buy

MA20

9.252

Buy

MA50

9.167

Buy

MA100

9.571

Sell

MA200

8.790

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Prothena Corporation PLC is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.52%, representing a quarter-over-quarter increase of 3.58%. The largest institutional shareholder is The Vanguard, holding a total of 2.14M shares, representing 3.98% of shares outstanding, with 69.82% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.90M

Scully (William P)

5.28M

-1.31%

Fennell (Todd W.)

4.50M

+3.33%

Rubric Capital Management LP

1.54M

BlackRock Institutional Trust Company, N.A.

2.97M

-4.92%

State Street Investment Management (US)

901.04K

-10.34%

The Vanguard Group, Inc.

Star Investors

2.05M

-5.43%

D. E. Shaw & Co., L.P.

1.32M

+236.00%

Armistice Capital LLC

1.82M

-18.43%

Adar1 Capital Management LLC

1.47M

-56.47%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Prothena Corporation PLC is 5.28, ranking 48 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.